Fri, Apr 25, 2014, 2:35 AM EDT - U.S. Markets open in 6 hrs 55 mins

Recent

% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

doodootoyou 12 posts  |  Last Activity: Aug 23, 2013 1:44 PM Member since: Jan 25, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • prescriptions. 10% growth is amazing.

  • Reply to

    $8.58!

    by wchang_98 Feb 5, 2013 11:26 AM
    doodootoyou doodootoyou Feb 5, 2013 11:36 AM Flag

    what's up with tsl? Why aren't you posting on it much anymore. Your chat is worth a lot more than the "serious" repetitious investors.

  • Reply to

    TA is just noises!

    by wchang_98 Feb 1, 2013 2:48 PM
    doodootoyou doodootoyou Feb 1, 2013 2:58 PM Flag

    like them both-- how's your family doing? Going to Japan soon, how about TSL- where is Mike?
    Enjoy the weekend.
    Jay

  • Reply to

    From Dec 19th SEC filing, exhibit 10A

    by doodootoyou Feb 1, 2013 10:23 AM
    doodootoyou doodootoyou Feb 1, 2013 12:05 PM Flag

    yes, I meant Disbrow.
    Please read the post SEC filing Dec 19th. I posted it in case you can't find it this morning-- it's an attachment AMPIO made to the filing. It's long and at the very end it shows Disbrow's milestones he must reach in order to vest his options.
    It is both good and bad. Good in that it shows that the company plans to get the stock to $5 within 6 months of the filing of the Dec 19th form. Bad in the sense it will be further dilution of shares. And that is not to mention the unstated intentions of management to sell their shares.
    I have no idea of Disbrow's connections with mutual funds/retirement funds managers to get this much money. No connections with ivy league graduates, but with someone(s) since he's done this with the previous company he has worked for.

  • The compensation milestones are hidden at the very end of the filing.
    Note the requirement of the stock price and the date by which this is to occur. It is number (4)

    Management milestones that affect cash bonuses


    1)

    Successful administration of any Ampion TM , Optina TM and Zertane TM clinical trials financed by the company. Successful shall mean that the trial was performed on time and on budget and with a demonstration of efficacy that is statistically significant and the drug is cleared for commercialization by the regulatory authorities in all countries in which commercialization is planned.


    2) Obtain, on terms favorable to the company, license agreement, partnerships or other collaborations for the commercialization of the company’s drug portfolio


    3) Obtain insurance reimbursement codes for each drug that receives regulatory clearance to commercialize


    4) Within 6 months of the date of this agreement, obtain $15 million in equity financing for the company at a share price in excess of $5/share

  • This is from latest filing- that is why the drop.
    On January 21, 2013, Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) entered into a Master Service Agreement and Scope of Work (the “Ampion Agreement”) with a clinical research organization (the “Ampion CRO”). Pursuant to the Ampion Agreement, the Ampion CRO will provide study management services in connection with the Company’s clinical trial of Ampion TM for the treatment of osteoarthritis of the knee. The consideration payable by Ampio to the Ampion CRO in connection with these services totals approximately $6.8 million, which is expected to be paid over the course of the next eleven months, subject to the achievement by the Ampion CRO of specified milestones. The Ampion Agreement is effective as of January 21, 2013 and continues until the Ampion Agreement is terminated in accordance with its terms. Either party may terminate the Ampion Agreement with or without cause upon 30 days written notice.

    On January 21, 2013, Ampio entered into a Master Services Agreement and Scope of Work (the “Optina Agreement”) with a clinical research organization (the “Optina CRO”). Pursuant to the Optina Agreement, the Optina CRO will provide clinical trial services in connection with the Company’s clinical trial of Optina TM for the treatment of diabetic macular edema. The consideration payable by Ampio to the Optina CRO in connection with these services totals approximately $6.0 million which is expected to be paid over the course of the next eleven months, based on specified milestones. The Optina Agreement is effective as of January 21, 2013 and continues until completion of the services, unless earlier terminated in accordance with the Optina Agreement.

  • Reply to

    Can we make it down 9 days in a row today?

    by superforce_57 Feb 1, 2013 8:33 AM
    doodootoyou doodootoyou Feb 1, 2013 10:09 AM Flag

    it's going to $5 again for sure for the new CFO has in his contract a requirement to get the stock to $5 within six months so the company can have another equity round for $15 million. That means by June 2013.
    Look at the latest 8K filing to see it. And if you need help finding it, I'll help you.

  • Reply to

    Hey Racavalli, need another SA pump!

    by ampiooooooh Jan 31, 2013 3:27 PM
    doodootoyou doodootoyou Jan 31, 2013 5:08 PM Flag

    is that Cavalli very likely a paid tote for AMPE. And the non-disclosure is pathetic.

  • doodootoyou by doodootoyou Jan 29, 2013 10:29 AM Flag

    My recommendation anyway.
    It'll easily hit that before it goes to $5 again.
    Please read the SEC filing on the new CFO. For his incentives to go into effect he is supposed to raise $15 million within 6 months with a share price of AT LEAST $5.
    So, for that to happen it needs to drop more so that fresh buyers can be enticed to place small bids on it going thru the roof.
    Retail investors like bargins, not new highs to place their bets on.
    This company is very likely NOT to create any new drugs, but just spin off hope/greed and do it for a couple years with the prospect of home runs.
    And those that think I'm a short seller need to look at the truth. To get to $3.5 it'll be like 100K shares. And again, I can not short at Scotttrade with stocks under $5-- and a lot of brokerages are the same. No real shorts would buy/short this stock for the volume is so tiny any demand at all spikes it. So there is no way they can cover any volume of shares without making the stock rocket. Also, see that short interest is 6% of the outstanding shares. And I think the shorting is the option holders.

  • Reply to

    Waiting game - .13 range 8.65 to 8.78

    by chrisanja Jan 25, 2013 10:52 AM
    doodootoyou doodootoyou Jan 25, 2013 2:49 PM Flag

    Low is close, because when it was under $8 that was without final approval for sales. Well, that's been given. So, likely will stay in the high $8 range for 10 more trading days. May dip to $8.25, but likely $8.5 will be a bottom.
    I agree fully that $10 and likely $11 will be broken within 40 trading days.

    Sentiment: Hold

  • Reply to

    What happened today?

    by superforce_57 Jan 23, 2013 3:38 PM
    doodootoyou doodootoyou Jan 25, 2013 2:45 PM Flag

    there is hardly any short interest- and most brokerages don't allow short under $5-- scottstrade, for instance, which is the one I use doesn't allow it.
    Also, the volume is miniscle, so any shorting done in a day-- say 50K shares, would only be $200K AND even that volume of shorting would strongly move the stock to the negative.
    Again, this is not a shorting stock for the volume and price is too small.
    What this stock is is a cash cow for the main stockholders and us outsiders are here simply to buy the hype and it'll prove to be worthless.
    Look up the patents that they hold--- go to the US Patent Office and type it in. Especially look up the patents filed in the past by the chief scientist.
    Also, look up the CEO's past. And what he did with his previous company. This is the SAME.
    You can make money with the stock, but only if you buy low-- like it's coming to $3.5 again likely shortly and within a month or two to $5 and back again.

  • Reply to

    What happened today?

    by superforce_57 Jan 23, 2013 3:38 PM
    doodootoyou doodootoyou Jan 25, 2013 12:31 PM Flag

    THe $5 was a test. Read the latest filing with the FED about the new COO. For his incentives to take effect he needs to raise $15 million in the next six months with a minimum stock price of $5.
    So, the stock is not going to break $5 until after the new stock issue is announced. They are gathering steam for that push.
    Also, this is pretty much a fake company and only the "believers" are going to get burned. Look up the history of the CEO.
    So, best to play this dopey stock as the owners are. Buy when it drops 25/30 percent and SELL on the next rise.
    I don't think they'll ever come out with a product, nor will it be sold. Just another shuckster company with disgusting owners that milk the public.

AMPE
5.73-0.05(-0.87%)Apr 24 4:04 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
GW Pharmaceuticals plc
NasdaqGMThu, Apr 24, 2014 4:00 PM EDT
Apple Inc.
NasdaqGSThu, Apr 24, 2014 4:00 PM EDT